Where does Deka Biosciences, Inc. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Deka Biosciences, Inc. ranks #12,406 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Deka Biosciences, Inc. hold?

Deka Biosciences, Inc. holds 24 US utility patents granted between 2020 and 2025, spanning 4 technology areas.

What is Deka Biosciences, Inc.'s Innovation Score?

Deka Biosciences, Inc. has an Innovation Score of 41.8 out of 100 (top 32% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Deka Biosciences, Inc. focus on?

Deka Biosciences, Inc.'s top technology area is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations) with 23 patents, ranking #848 of 6,058 assignees active in that subclass. Grants appear in 4 CPC subclasses total.

Is Deka Biosciences, Inc.'s patent grant rate increasing or decreasing?

Insufficient historical data is available to calculate a velocity trend for Deka Biosciences, Inc..

What does claim depth mean for Deka Biosciences, Inc.'s patents?

Deka Biosciences, Inc.'s patents average 6.1 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Deka Biosciences, Inc. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView US Corporation

Deka Biosciences, Inc.

USPTO PatentsView assignee record - 24 granted patents across 4 technology areas, recorded in grant years 2020–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Deka ranks #12,406 of 49,997 tracked US assignees by granted-patent volume, with 24 patents across 4 technology areas.

#12,406
of 49,997 US assignees by volume: Top 32%
by Innovation Score (41.8/100): 6.1
avg claims per patent

USPTO PatentsView assignee plate

Corpus R12406 · US Corporation #12,406 · 24 grants

GRANTS-SMALL · UPPER-Q · PHOTO-FINISH · CPC-NARROW · INNOV-PAR · CLAIMS-SPARSE · TYPE-USCORP · SPAN-YRS · BOOK-RICH

GRANTS-SMALL 24 grants
UPPER-Q #12,406/49,997
PHOTO-FINISH Cumberland Pharmaceu…
CPC-NARROW A61P · 4 areas
INNOV-PAR 41.8/100
CLAIMS-SPARSE 6.1 claims/avg
TYPE-USCORP US Corporation
SPAN-YRS 2020–2025 · 6y
BOOK-RICH 9/10 fields

Nearest grant-volume peer: Cumberland Pharmaceuticals Inc. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Deka’s 41.8 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 11.1 pts (27%) Velocity 20.0 pts (48%) Breadth 7.1 pts (17%) Claim depth 3.6 pts (9%)

Qualcomm Incorporated · highest

85
Deka Biosciences · this assignee

42
3D Lighting… · lowest

7

What this shows Deka's Innovation Score is 41.8/100 (top 32% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Deka?

Each dot is one of Deka’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Deka’s own 6.1 claims/patent is at or below the 11.8 median for these volume peers. Volume here does not track with deeper claims; several lower-volume peers claim more thoroughly per patent.

Deka vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Deka's grants concentrate

Deka Biosciences, Inc. is a focused PatentsView assignee: 4 CPC subclasses with 95.8% of grants classified under A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations). Peak complete grant year is 2024 (11 grants) versus a trough of 1 in 2020. By volume, Deka sits between Cumberland Pharmaceuticals Inc. and Digital Surgery Limited.

Deka's three-year grant acceleration

Deka Biosciences, Inc. shows 17 grants in 2022–2024 against only 5 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Cumberland Pharma…

24
Cyclerion Therape…

24
Cyral

24
D-link

24
Delfortgroup

24
Denka Seiken

24
Dentsu

24
Digital Surgery

24
Deka Biosciences ◀

24

What this shows Deka holds 24 patents at rank #12,402, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Deka

By rank, the assignees closest to #12,402 in granted patent volume.

Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)

Other assignees with the most granted patents in Deka's primary technology class.

Deka's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

42 Top 32% higher than 68% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2020–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2020–2019 baseline. Full figures in the table below.

View data table

Deka Biosciences, Inc. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2020	1	4.2%
2021	4	16.7%
2022	1	4.2%
2023	5	20.8%
2024	11	45.8%
2025partial year	2	8.3%

Which technologies does Deka Biosciences, Inc. patent most?

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 23

C07K - Peptides 23

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 23

Y02A - Technologies FOR Adaptation TO Climate Change 5

Top 4 of 4 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Deka Biosciences, Inc.'s patent record in context - here's where to go next.

Deka Biosciences, Inc.'s lead technology class is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations), 95.8% of its portfolio - see every assignee active in that class. Explore A61P
Ranked #12,406 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Deka Biosciences, Inc. against Cumberland Pharmaceuticals Inc., an assignee filing at a similar volume. Compare portfolios
Innovation Score of 41.8/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.